Profile data is unavailable for this security.
About the company
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
- Revenue in GBP (TTM)56.04m
- Net income in GBP16.12m
- Incorporated2011
- Employees274.00
- LocationhVIVO PLC42 New RoadLONDON E1 2AXUnited KingdomGBR
- Phone+44 289 073 7900
- Websitehttps://hvivo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Futura Medical PLC | 3.10m | -6.51m | 110.03m | 12.00 | -- | 20.09 | -- | 35.48 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 4.73 | -- | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | -- | -- | -- | -- | -11.40 | -- | 219.68 | -- |
Creo Medical Group PLC | 29.23m | -25.10m | 124.71m | 279.00 | -- | 1.75 | -- | 4.27 | -0.1139 | -0.1139 | 0.126 | 0.1966 | 0.3318 | 1.87 | 4.14 | 102,926.10 | -28.49 | -- | -34.24 | -- | 48.11 | -- | -85.87 | -- | 3.45 | -- | 0.1177 | -- | 7.98 | -- | -9.52 | -- | -- | -- |
Animalcare Group Plc | 74.35m | 1.20m | 130.43m | 220.00 | 109.76 | 1.67 | 14.80 | 1.75 | 0.0198 | 0.0198 | 1.22 | 1.30 | 0.6608 | 2.63 | 5.54 | -- | 1.07 | 0.3272 | 1.30 | 0.3866 | 58.30 | 53.62 | 1.61 | 0.5484 | 1.05 | 5.44 | 0.0701 | 599.95 | 3.82 | 0.5138 | -38.98 | -- | -11.79 | 2.59 |
4Basebio PLC | 354.00k | -6.28m | 132.53m | -- | -- | 37.38 | -- | 374.39 | -0.5094 | -0.5094 | 0.0287 | 0.2769 | 0.0296 | 0.3977 | 4.88 | -- | -52.42 | -- | -60.21 | -- | 80.51 | -- | -1,772.60 | -- | 3.28 | -40.29 | 0.6683 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
Allergy Therapeutics plc | 53.26m | -50.22m | 135.84m | 635.00 | -- | 5.13 | -- | 2.55 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
Avacta Group Plc | 16.03m | -42.08m | 174.38m | 120.00 | -- | 6.02 | -- | 10.88 | -0.1605 | -0.1633 | 0.0606 | 0.0826 | 0.2406 | 4.50 | 2.38 | 133,541.70 | -63.18 | -- | -119.23 | -- | 54.40 | -- | -262.60 | -- | 0.6603 | -1.66 | 0.6913 | -- | 228.22 | -- | -49.92 | -- | -- | -- |
hVIVO PLC | 56.04m | 16.12m | 187.78m | 274.00 | 11.80 | 5.47 | 9.97 | 3.35 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
Oxford BioMedica plc | 119.02m | -61.63m | 190.40m | 891.00 | -- | 1.07 | -- | 1.60 | -0.6389 | -0.6389 | 1.23 | 1.78 | 0.2743 | 4.67 | 3.09 | 131,662.60 | -16.18 | -4.45 | -21.95 | -5.69 | 46.20 | 53.90 | -58.97 | -8.16 | 3.07 | -9.24 | 0.3635 | -- | -1.97 | 30.08 | -305.97 | -- | 52.60 | -- |
Alliance Pharma plc | 170.05m | -7.06m | 197.79m | 249.00 | -- | 0.7138 | 63.15 | 1.16 | -0.0131 | -0.0131 | 0.3145 | 0.5127 | 0.3202 | 2.88 | 4.40 | 682,927.70 | -1.33 | 2.64 | -1.47 | 2.95 | 57.58 | 63.38 | -4.15 | 8.35 | 1.38 | 2.18 | 0.31 | 53.41 | 2.58 | 10.50 | -87.21 | -49.62 | -25.78 | 5.94 |
Bioventix PLC | 13.60m | 8.67m | 240.10m | 16.00 | 28.18 | 21.00 | 27.32 | 17.66 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
Niox Group PLC | 36.80m | 9.50m | 274.79m | 85.00 | 30.75 | 3.04 | 19.77 | 7.47 | 0.0211 | 0.0238 | 0.0819 | 0.2136 | 0.3874 | 2.31 | 6.13 | 432,941.20 | 10.00 | -2.41 | 10.57 | -2.90 | 72.01 | 70.87 | 25.82 | -11.46 | 3.99 | -- | 0.013 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
Holder | Shares | % Held |
---|---|---|
JPMorgan Asset Management (UK) Ltd.as of 21 Mar 2024 | 35.18m | 5.17% |
Canaccord Genuity Wealth Ltd.as of 29 Dec 2023 | 21.68m | 3.19% |
Octopus Investments Ltd.as of 28 Mar 2024 | 14.18m | 2.08% |
Liontrust Investment Partners LLPas of 29 Feb 2024 | 10.37m | 1.52% |
Thornbridge Investment Management LLPas of 31 Oct 2022 | 9.97m | 1.47% |
Mandarine Gestion SAas of 30 Jun 2023 | 7.00m | 1.03% |
Janus Henderson Investors UK Ltd.as of 29 Feb 2024 | 3.99m | 0.59% |
River Global Investors LLPas of 29 Feb 2024 | 1.30m | 0.19% |
Margetts Fund Management Ltd.as of 31 Aug 2023 | 623.21k | 0.09% |
Lazard Asset Management LLCas of 31 Mar 2024 | 326.59k | 0.05% |